

Institutional Biosafety Committee - Regular Meeting

Thursday, December 04, 2025

Zoom

Meeting Minutes

VOTING MEMBERS PRESENT:	G. Babcock, K. Burns, J. Corcoran, G. Dean, M. Espinola, S. Kasper, R. Larson, E. Otten, E. Serafin, T. Rausch, F. Schaefer
VOTING MEMBERS NOT PRESENT:	S. Apewokin, D. Elsaesser, J. Yu
AD HOC MEMBERS/CONSULTANTS/GUESTS:	A. Anukanth, T. Gulley, A. Perry, J. Strasser
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 12:00 p.m.

- I. **Conflicts of Interest** - No conflicts were identified.
- II. **Minutes** - Minutes from the previous IBC meeting (11/06/25) were approved (10: YES/0: NO/0: Abstained)
- III. **Old Business** - No old business was discussed
- IV. **New Business**
 - A. **Primary Protocols** (2 protocols)

S.Kasper joined the meeting at 12:07 p.m.

IBC Protocol Number	PI	Type of Submission	IBC Items	
1. 25-11-04-01	Latif	New Clinical	CAR-T cells	
IBC Requests:	<u>IBC Form</u> <div>1. Section I. A - Provide the UC mail code;</div> <div>2. Section I. B -Provide BBP transcripts for clinical staff;</div> <div>3. Section II. B - Reword abstract removing "informed-consent language" (second-person pronoun: you);</div> <div>4. Section II. C. 1 - Gene Name - In the field referring to attachment, add that document can be found in Section II. A;</div> <div>5. Section II. C. 4 - For clarity, in "Additional Information", state that vector is not directly administered into patients. Instead, patients will receive virally transduced cells;</div> <div>6. Section III. A - Location #2 - Provide the room number at BCHC</div>			
	Motion	Approve upon modifications addressing outlined issues.		
Voting Result & Dual Use	YES: 10 <i>One member did not vote</i>	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-11-03-01	Miller-Handley	New	BSL2	<i>in vitro</i> : HDM (blood, kidney tissue/biopsy, urine) <i>in vitro</i> and <i>in vivo</i> : <i>Listeria monocytogenes</i> and Influenza virus (PR8)

IBC Requests:	<u>Main Form – General Safety:</u>			
	1. Section I. D - Confirm which room(s) have a biosafety cabinet (BSC);			
	2. Section II. B - Provide more rationale/detail about how the infectious agents (<i>L. monocytogenes</i> , influenza virus) are used in this research;			
	3. Section III. A - If the homogenizer will be used in a BSC (or chemical fume hood) for potentially infectious materials, include relevant information;			
	4. Section III. B - Check YES for "Additional Information" and list the types of sharps that are disposed of in the sharps containers;			
	5. Section III. C - Check YES for "Additional Information" and indicate when Fluid Resistant Lab Coat/Gown and Safety Goggles are used;			
	6. Section V - Check YES for “Additional Information” and describe when the different disinfectants are used.			
	<u>Form B – Microbial/Infectious Agents</u>			
	7. Agents #1 and #2 - Indicate the institution for Dr. Way;			
	8. Agents # 1 and #2 - Agent's Characteristics - last sentence - "bleed" should read "bleach";			
9. Agents #1, #2 and #3 - Use <i>in vitro</i> - If agents are propagated/grown in the lab, check YES and state that they are;				
10. Agent #3 - Agent’s Characteristics – Replace "severe cause" with "severe cases" and describe the PR8 strain;				
<u>Form C – Human and NHP Derived Materials:</u>				
11. Form C - Section I - Table - Blood, serum, plasma - change to "who are experiencing" and in “Description & Source”, -indicate from where the human materials listed are obtained.				
12. Section II. A - Change "collected <u>an</u> " to "collected <u>and</u> ".				
<u>Form D – Biohazard in Animals:</u>				
13. Section II - Animals receiving bacteria (i.e. <i>L. monocytogenes</i>) should never be housed in LAMS standard area. Uncheck "standard housing" box;				
14. Section III. A - Describe the activities which might lead to potential exposure (e.g. handling/administration, needle stick);				
15. Section III. C - Check YES for "Additional Information" and list types of sharps that are disposed of in the sharps containers;				
16. Section III. C - If your animal procedures are performed exclusively in LAMS, uncheck the box for "bedding dump stations" since they do not have this type of equipment.				
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 11	NO: 0	Abstained: 0	Dual Use? No

Dual Use	One member did not vote			
----------	-------------------------	--	--	--

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-11-19-01	Norton	Renewal	BSL2	<u>in vitro</u> : HDM (saliva, skin swab)
IBC Requests:	Main Form – General Safety: 1. Section III. C - Check YES for "Additional Information" and indicate when Safety Goggles and Face Shield are used.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 11	NO: 0	Abstained: 0	Dual Use? No

V. Other New Business

The next IBC meeting falls on New Year's Day (01/01/26); therefore, an email will be sent to members to reschedule it for January 8, 2026.

VI. Protocol Updates October 29th to November 26th - 13 protocols

1. IBC# 25-02-13-01 - PI: Wang- Personnel and PI Reassignment
2. IBC# 23-10-19-02 - PI: Madan - Secondary Contact and Personnel
3. IBC# 24-01-20-02 - PI: Scaglioni - Personnel
4. IBC# 24-06-18-02 - PI: Hertlein - Personnel
5. IBC# 24-06-18-02 - PI: Thompson T - Personnel
6. IBC# 24-03-06-01 - PI: Luo - Personnel, Location
7. IBC# 24-03-08-02 - PI: Hyacinth - Personnel
8. IBC# 22-11-17-01 – PI: Kotagiri - Personnel
9. IBC# 25-07-08-01 - PI: Brewer - Secondary Contact and Personnel
10. IBC# 25-07-08-01 - PI: Apewokin - Secondary Contact and Personnel
11. IBC# 25-05-23-01 - PI: Lewis - Personnel
12. IBC# 25-10-20-03 - PI: Li - Location
13. IBC# 24-01-02-01 - PI: Waltz - Personnel

VI. Reports

- A. IBC/BSOf (M. Espinola)
 - NIH/OSP is having listening sessions related to modernization and strengthening oversight for biosafety, designated for each region.
 - There is a listening session for region 3 (Ohio) on January 15th, 2026.
 - M. Espinola will share the link for registration. Committee members can register to voice their opinion.

VII. Educational Materials/Updates

- A. [FDA Warning](#). U.S. Food and Drug Administration, November 2025.
- B. [RfK Jr. says the Trump administration is following 'gold standard' science. Here's what to know](#) PBS News - Health, November 2025

K. Burns adjourned the meeting at 12:22 p.m.

